Solutio™ catheter

CAUTION: For investigational use only. The Solutio catheter has not been evaluated by the FDA and is not available for sale in the USA.

Latest news

SolutioTM featured on stage at the European Venous Forum in Athens

July 1, 2024
Our founder Dr. Michael Åkesson was invited to present the results from our first-in-man clinical study at the European Venous Forum in Athens last…

Vinnova awards MedVasc a grant for a better understanding of reimbursement in the US

May 24, 2024
MedVasc has been awarded a grant of SEK 135,000 from Vinnova (Swedish Innovation Agency) to enhance the company’s understanding of the reimbursement landscape in…

SolutioTM featured on center stage at 2024 International Venous Conference

May 3, 2024
MedVasc anesthesia catheter SolutioTM gained attention during 2024 International Venous Conference as renowned KOL Dr. Lowell Kabnick gave a talk about next-generation venous devices:   …

Changing the anesthesia procedure

With only one injection, instead of several injections through the skin, the Solutio catheter deploys local anesthesia from inside the vein, making the anesthesia procedure less painful for the patient, and more efficient for the clinician. The technology is developed from a clinical need and our first-in-man proved Solutio to be safe to use while significantly lowering pain in the process of deploying local anesthesia prior to performing thermal ablation of varicose veins. The Solutio catheter is compatible with a vast amount of treatment catheters in the market.

The Solutio catheter

Be the first one to try the Solutio catheter, sign up to get more information.

Based on years of experience

MedVasc AB was founded in 2013 by Michael Åkesson and has during the last years, developed a final prototype, been granted patents and trademarks in all prioritized markets, and performed a first-in-man clinical study. During 2023 MedVasc have initiated the FDA 510k process to gain a regulatory pathway towards FDA clearance.

Dr. Michael Åkesson – Board Member, Founder and CMO